Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis

被引：0

作者：

Bresse, Xavier ^{[1
]}

Annemans, Lieven ^{[2
]}

Preaud, Emmanuelle ^{[1
]}

Bloch, Karine ^{[1
]}

Duru, Gerard ^{[3
]}

Gauthier, Aline ^{[4
]}

机构：

[1] Sanofi Pasteur MSD, F-69367 Lyon 07, France

[2] Univ Ghent, B-9000 Ghent, Belgium

[3] CYKLAD Grp, F-69130 Rillieux La Pape, France

[4] Amaris, London NW1 8NZ, England

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2013年 / 13卷 / 03期

关键词：

cost-effectiveness; herpes zoster; herpes zoster vaccine; postherpetic neuralgia; vaccination; QUALITY-OF-LIFE; ECONOMIC-EVALUATION; HEALTH-CARE; PAIN; PREVENTION; SHINGLES; BURDEN; VARICELLA; IMPACT; EPIDEMIOLOGY;

D O I：

10.1586/ERP.13.19

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

This study assesses the cost-effectiveness of vaccination against herpes zoster (HZ) and postherpetic neuralgia in France, using a published Markov model. The cost-effectiveness of vaccinating individuals aged from 65 years or between 70 and 79 years was evaluated over their lifetime, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol five-dimension questionnaire) utilities from the literature. HZ vaccination was highly cost effective in both populations. Incremental cost-effective ratios were estimated between (sic)9513 and 12,304 per quality-adjusted life year gained, corresponding to (sic)2240-2651 per HZ case avoided and (sic)3539-4395 per postherpetic neuralgia case avoided. In addition to epidemiological and clinical evidence, economic evidence also supports the implementation of HZ vaccination in France.

引用

页码：393 / 406

页数：14

共 50 条

[21] Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia
Betts, Robert E.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 57 (06) : S143 - S147
[22] HEALTH ECONOMIC EVALUATION OF THE VACCINATION AGAINST HERPES ZOSTER AND POSTHERPETIC NEURALGIA IN GERMANY
Ultsch, B.
Reinhold, T.
Siedler, A.
Krause, G.
Wichmann, O.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A394 - A394
[23] Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales
van Hoek, A. J.
Gay, N.
Melegaro, A.
Opstelten, W.
Edmunds, W. J.
[J]. VACCINE, 2009, 27 (09) : 1454 - 1467
[24] COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN HONG KONG
Lee, C.
You, J.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A583 - A584
[25] Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
Pellissier, James M.
Brisson, Marc
Levin, Myron J.
[J]. VACCINE, 2007, 25 (49) : 8326 - 8337
[26] Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
Bernhard Ultsch
Ingrid Köster
Thomas Reinhold
Anette Siedler
Gérard Krause
Andrea Icks
Ingrid Schubert
Ole Wichmann
[J]. The European Journal of Health Economics, 2013, 14 : 1015 - 1026
[27] Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
Ultsch, Bernhard
Koester, Ingrid
Reinhold, Thomas
Siedler, Anette
Krause, Gerard
Icks, Andrea
Schubert, Ingrid
Wichmann, Ole
[J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (06): : 1015 - 1026
[28] Herpes zoster and postherpetic Neuralgia
Wollina, U.
Machetanz, J.
[J]. HAUTARZT, 2016, 67 (08): : 653 - 663
[29] Herpes zoster and postherpetic neuralgia
Watson, C. Peter N.
[J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (16) : 1713 - 1714
[30] Herpes zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in New Zealand: a retrospective cohort study
Mbinta, James F.
Wang, Alex X.
Nguyen, Binh P.
Paynter, Janine
Awuni, Prosper Mandela A.
Pine, Russell
Sporle, Andrew A.
Simpson, Colin R.
[J]. LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 31

← 1 2 3 4 5 →